MolMed S.p.A. and AbCheck s.r.o announced that they have entered into a three-year Master Agreement aimed at providing MolMed with selected and optimized antibodies for the development of new Chimeric Antigen Receptors (CARs), targeting both liquid and solid tumors. Under the agreement, AbCheck will use its proprietary discovery platform to select, optimize and deliver multiple human single-chain variable fragments (scFvs), specifically recognizing each MolMed target candidate. ScFvs are the extracellular regions of the CAR responsible for antigen recognition and binding, conferring specificity to the CAR. The new and optimized scFvs delivered by AbCheck will allow MolMed to expand its proprietary pipeline in both autologous CAR-T and future allogenic CAR-NK platforms.